Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Pricing Details Set Out Ahead Of 3 October Launch For Cimerli Biosimilar Version Of Lucentis
Executive Summary
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.